Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clearmind MedicineCMND -5.67%22 EV-to-EBIT is 1.37 as of Sep. 01, 2026. GuruFocus rates CMND with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 366 Biotechnology companies, Clearmind Medicine ranks better than 77.32% on this metric.
Clearmind Medicine (NAS:CMND) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Clearmind Medicine's Enterprise Value for the quarter that ended in Apr. 2026 was $-6.25 Mil.
Clearmind Medicine's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearmind Medicine EV-to-EBIT Related Terms
Clearmind Medicine EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Clearmind Medicine's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Clearmind Medicine's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearmind Medicine EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearmind Medicine's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Clearmind Medicine's EV-to-EBIT falls into.
Clearmind Medicine's current Enterprise Value is $-10.79 Mil.
Clearmind Medicine's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearmind Medicine (CMND) has a EV-to-EBIT of 1.37 as of Sep. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Clearmind Medicine and its competitors. According to the industry distribution chart, Clearmind Medicine ranks #83 out of 366 companies in the Biotechnology industry, placing it in the top 22.7%.
Is Clearmind Medicine's EV-to-EBIT too high?
Clearmind Medicine's current EV-to-EBIT is 1.37. The Biotechnology industry median EV-to-EBIT is 15.55. Clearmind Medicine's value of 1.37 is 91.2% below this industry median. Based on the distribution chart, Clearmind Medicine ranks #83 out of 366 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clearmind Medicine has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Clearmind Medicine's EV-to-EBIT compare to CASIF and BIXT?
According to the Biotechnology industry distribution chart, Clearmind Medicine ranks #83 out of 366 companies for EV-to-EBIT. This places Clearmind Medicine in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.55. Clearmind Medicine's value of 1.37 is 91.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.55, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clearmind Medicine's current EV-to-EBIT of 1.37 is 91.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Clearmind Medicine and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearmind Medicine's current EV-to-EBIT is 1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearmind Medicine stock overvalued right now?
Clearmind Medicine (CMND) has a current EV-to-EBIT of 1.37. The current EV-to-EBIT is 1.37 and 91.2% below the Biotechnology industry median of 15.55. Clearmind Medicine's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Clearmind Medicine (CMND), the current EV-to-EBIT is 1.37 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
22GF Score
Get the complete analysis for CMND
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMND has been successfully added to your 
